Retension Pharmaceuticals, Inc. — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Retension Pharmaceuticals hired Robert Wong as Vice President, Chief Accounting Officer, effective November 2, 2026, at $360,000 annual base salary ($30,000/month) plus 25,000 non-qualified stock options (10-year term, 4-year vesting schedule), a $20,000 one-time bonus (if employed through March 31, 2027), and up to 30% annual bonus. Wong will serve as principal accounting officer, sign SEC filings, and participate in executive severance plan (contingent on company raising ≥$15M). Employment is at-will.
Why this rating
Routine C-suite hiring; $360K salary is modest, suggesting early-stage biotech. No material business impact disclosed. No company size data to confirm materiality.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.